Literature DB >> 28992258

Risk and complications of venous thromboembolism in dialysis patients.

Amber O Molnar1,2,3, Sarah E Bota1, Eric McArthur1, Ngan N Lam4, Amit X Garg1,5, Ron Wald1,6, Deborah Zimmerman7, Manish M Sood1,7,8.   

Abstract

Background: Contemporary data on venous thromboembolism (VTE) risk in dialysis patients are limited. Our objective was to determine the risk and complications of VTE among incident maintenance dialysis patients.
Methods: We performed a retrospective cohort study using administrative databases. We included adult incident dialysis patients from 2004 to 2010 (n = 13 315). Dialysis patients were age- and sex-matched to individuals of the general population using a 1:4 ratio (n = 53 260). We determined the 3-year cumulative incidence and incidence rate (IR) of VTE, pulmonary embolism (PE) and deep venous thrombosis (DVT). We examined outcomes of bleeding and all-cause mortality following a VTE event among matched dialysis patients who did and did not experience a VTE. We used Cox proportional hazards regression models, stratified on matched sets, to calculate the hazard ratios (HRs) for all outcomes of interest.
Results: VTE occurred in 1114 (8.4%) dialysis patients compared with 1233 (2.3%) individuals in the general population {IR 37.1 versus 8.1 per 1000 person-years; HR 4.5 [95% confidence interval (CI) 4.1-4.9]; adjusted HR 2.9 (95% CI 2.6-3.4)}. Both components of VTE [PE and DVT; adjusted HR 4.0 (95% CI 2.9-5.6) and HR 2.8 (95% CI 2.4-3.2), respectively] occurred more frequently in dialysis patients. Compared with dialysis patients without a VTE, those with a VTE had a higher risk of bleeding [adjusted HR 2.0 (95% CI 1.3-2.9)] and all-cause mortality [adjusted HR 2.4 (95% CI 2.0-2.8)]. Conclusions: VTE is common in dialysis patients and confers a high risk of major bleeding and all-cause mortality. Thromboprophylaxis and VTE treatment studies in dialysis patients are needed.

Entities:  

Mesh:

Year:  2018        PMID: 28992258     DOI: 10.1093/ndt/gfx212

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study.

Authors:  Nicholas S Roetker; Haifeng Guo; Dena Rosen Ramey; Ciaran J McMullan; G Brandon Atkins; James B Wetmore
Journal:  Kidney Med       Date:  2022-03-24

2.  Anticoagulant strategies for the patient with chronic kidney disease.

Authors:  Jonathan P Law; Luke Pickup; Jonathan N Townend; Charles J Ferro
Journal:  Clin Med (Lond)       Date:  2020-03       Impact factor: 2.659

Review 3.  Providing Care for Transgender Persons With Kidney Disease: A Narrative Review.

Authors:  David Collister; Nathalie Saad; Emily Christie; Sofia Ahmed
Journal:  Can J Kidney Health Dis       Date:  2021-01-20

4.  The Safety of Direct Oral Anticoagulants Versus Warfarin Among Older Individuals With Acute Venous Thromboembolism and CKD: A Population-Based Cohort Study.

Authors:  Ziv Harel; Nivethika Jeyakumar; Bin Luo; Samuel A Silver; Ayub Akbari; Amber O Molnar; Manish M Sood
Journal:  Kidney Med       Date:  2022-07-03

5.  SARS-CoV-2 assessment in an outpatient dialysis facility of a single center in Brazil.

Authors:  Fernanda Salomão Gorayeb-Polacchini; Heloisa Cristina Caldas; Angelica Canovas Bottazzo; Mario Abbud-Filho
Journal:  Braz J Infect Dis       Date:  2021-07-06       Impact factor: 3.257

6.  Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.

Authors:  Tania Ahuja; Kelly Sessa; Cristian Merchan; John Papadopoulos; David Green
Journal:  Adv Hematol       Date:  2021-01-29

7.  Effect of renal dialysis on mortality and complications following hip fracture surgery in elderly patients: A population based retrospective cohort study.

Authors:  Eun-Jin Ahn; Si Ra Bang
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.